STOCK DUELS
AstraZeneca vs Eli Lilly - Official head-to-head comparisons for widely followed pairs.
Official Stock Duel · AZN/LLYPublished
AstraZeneca vs Eli Lilly
Compares AstraZeneca and Eli Lilly across growth, profitability, cash generation, valuation and balance-sheet signals.
Left side
AZN.LSE
Right side
LLY
Comparison categories
6
Generated: Jul 14, 2026, 04:33 AM
Data as of: 2026-07-13
Stock Duels· 23 analyses
Official head-to-head comparisons for widely followed pairs.
Head-to-Head
AZN
AstraZeneca PLC
2VS4
metrics
LLY
Eli Lilly and Company
9.93%
Sales Growth
47.44%
23.51%
Return on Equity (ROE)
107.64%
15.95%
Return on Invested Capital (ROIC)
37.34%
$8.8B
Free Cash Flow
$13.6B
25.6
Price to Earnings (P/E)
41.89
14.33
EV/EBITDA
32.78
Datafin’s View
Two pharma momentum stories: AstraZeneca’s oncology depth against Eli Lilly’s obesity-driven surge.
A diversified pipeline or the momentum of a single mega-product — two routes to growth in pharma. AstraZeneca’s depth in oncology spreads its risk across many shots on goal, while Eli Lilly rides an extraordinary obesity-driven surge that concentrates both the upside and the expectations.
This analysis is for informational purposes only and is not investment advice; it is a repeatable research starting point using the same rules.
Factor Profile
AZN.LSE and LLY are compared inside each metric family.
Results
Latest published or live-generated results from the official Datafin analysis.
| # | Stock | Winner | Sales Growth | Return on Equity(ROE) | Return on Invested Capital(ROIC) | Free Cash Flow | Price to Earnings(P/E) | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 🇸🇪 | AZN.ST AstraZeneca PLC | - | 9.93% | 23.51% | 15.95% | $8.8B | 25.6 | 14.33 |
| 2 | 🇺🇸 | LLY.US Eli Lilly and Company | 47.44% | 107.64% | 37.34% | $13.6B | 41.89 | 32.78 |
1🇸🇪
AZN.ST
AstraZeneca PLC
- Sales Growth
- 9.93%
- Return on Equity(ROE)
- 23.51%
- Return on Invested Capital(ROIC)
- 15.95%
- Free Cash Flow
- $8.8B
- Price to Earnings(P/E)
- 25.6
- EV/EBITDA
- 14.33
2🇺🇸
LLY.US
Eli Lilly and Company
- Sales Growth
- 47.44%
- Return on Equity(ROE)
- 107.64%
- Return on Invested Capital(ROIC)
- 37.34%
- Free Cash Flow
- $13.6B
- Price to Earnings(P/E)
- 41.89
- EV/EBITDA
- 32.78
Methodology
Revenue Growthhigher is better
ROEhigher is better
ROIChigher is better
Free Cash Flowhigher is better
P/Elower is better
EV/EBITDAlower is better
Last 5 Updates
Jul 14, 2026, 04:33 AM2 companies
List unchanged (refreshed).
Jun 30, 2026, 12:32 PM2 companies
Entered:AZN.ST
Exited:AZN.LSE
May 31, 2026, 08:32 AM2 companies
First run.